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To the Editor: Tentori et al.1 reported a 20% increased risk of
mortality in dialysis patients who were not taking intrave-
nous vitamin D compared to those who received vitamin D,
confirming studies showing a survival benefit in patients
administered vitamin D.2–4 However, Tentori et al. claim
there was no differences in mortality risk when comparing
the use of calcitriol (1a,25-dihydroxyvitamin D3) with
doxercalciferol (1a-hydroxyvitamin D2) and paricalcitol
(19-nor-1a,25-dihydroxyvitamin D2). Unfortunately, there
are significant limitations with their analyses, and subsequent
conclusions. The authors have taken liberty in their claim of
‘equivalency’ between doxercalciferol and paricalcitol and in
their comparison to previous studies that employed larger
databases and longer treatment periods.2–4
It is unclear if the authors understand the differences
between the various vitamin D compounds. Although both
paricalcitol and doxercalciferol are D2, whereas calcitriol is a
D3 compound, the major differentiating factor in the
activation of the vitamin D receptor (VDR) is that
paricalcitol has a modification in the A ring. In fact,
doxercalciferol is an inactive pro-hormone that has to be
converted by the liver to its active form (1a,25-dihydroxy-
vitamin D2) and it is unclear if there are differences in the
activation of the VDR by 1a,25-D3 or 1a,25-D2. Thus, it is
misleading when the authors equate paricalcitol and
doxercalciferol by referring to them collectively as D2
compounds.
Important limitations of this study include the relatively
small number of patients and the fact that the treatments
were not simultaneous but sequential and short in duration.
There were 7731 patients who received vitamin D at any time
and the median observation period was less than 10 months.
Patients who received calcitriol started sooner after initiating
dialysis, were not dosed according to KDOQI guidelines and
were started on therapy earlier in the study period than those
receiving other compounds, whereas those who received
doxercalciferol had the shortest follow-up and were started on
therapy later in the study period. Moreover, only about 50% of
the treated patients received vitamin D for more than 6 months.
The high rate of censoring was largely due to patients being
switched from one D compound to another (38%). It is likely
that the study was underpowered to show a 12–16% survival
difference between calcitriol and paricalcitol as was demon-
strated by Teng et al. after evaluation of 67 399 patients.2
On the basis of these limitations, the authors should
acknowledge that they were unable to show survival
differences among the vitamin D treatment groups in large
part because the study was underpowered and the design was
not appropriate to make a statement of equivalence. This
would be a fairer interpretation of their data than the
inappropriate claim that the major finding of the study was
the lack of a survival difference between paricalcitol and
doxercalciferol. In addition to the impact on patient care,
there is an enormous financial stake associated with the use
of these compounds. Thus, before coming to conclusions
regarding the effect of vitamin D in general and the relative
effect of different compounds in particular, appropriately
designed and powered studies are required to determine the
best practice for reducing mortality associated with chronic
kidney disease.
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We appreciate Dr Sprague’s letter1 to our article.2
Doxercalciferol undergoes hepatic conversion to its active
form (1,25-dihydroxyvitamin D2), but once activated, it is
a vitamin D2 analog.
Dialysis Clinic Inc. (DCI) is a large not-for-profit
provider. Procedural differences between DCI and for-
profit providers may influence clinical outcomes. The use
of an incident versus a prevalent cohort reduced our
sample size and the impact of potential confounders. The
crude mortality rate (deaths/100 patient years, 95%
confidence interval (CI)) was higher among patients
receiving calcitriol (19.6, 18.2–21.1) versus paricalcitol
(15.3, 13.6–16.9) (Po0.0001) or doxercalciferol (15.4,
13.6–17.1) (P¼ 0.0003). However, in our Cox models,
administration of paricalcitol and doxercalciferol versus
calcitriol was associated with a survival benefit only in the
unadjusted model and the model adjusted for demo-
graphics, reflecting our relatively small sample. Never-
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theless, in our fully adjusted model, the 95% CI for the
hazard ratio associated with the administration of
paricalcitol versus calcitriol included the point estimate
reported by Teng et al.3 Paricalcitol appears to confer
no survival advantage over doxercalciferol. The point
estimates for hazard ratios for doxercalciferol versus
paricalcitol ranged from 0.99 to 1.06 and each 95% CI
included 1.0. However, we cannot exclude the possibility
that doxercalciferol may be associated with a small benefit
or disadvantage over paracalciferol.
Our retrospective study reflects clinical practice. Since
different vitamin D preparations became available at
different times, the treatments were not simultaneous, and
switching was the major cause of censoring. The vitamin D
analogs were not dosed according to KDOQI guidelines,
since most of the study occurred before these were published.
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To the Editor: In their comparison of immunofluorescence
(IF) on frozen sections with pronase-digested paraffin
sections, Nasr et al.1 found that pronase digestion was a
useful technique for IF on paraffin (IF-P) sections. However,
the sensitivity of this technique was low for membranous
glomerulopathy and anti-glomerular basement membrane
disease (50 and 20%, respectively), which was mainly due
to weak staining of IgG (immunoglobulin G).
In our laboratory, we use bacterial proteinase XXIV
(Sigma, St Louis, MO, USA), as described by Bancroft and
Gamble,2 instead of pronase. We compared IF-P on
proteinase XXIV- and pronase-digested paraffin sections.
We selected five cases of lupus nephritis that showed full-
house fluorescence staining on frozen sections. In all cases,
staining intensity was similar or better on proteinase XXIV-
digested slides, and less background was observed. Impor-
tantly, staining for IgG and C1q was more intense in sections
digested with proteinase XXIV than in those digested with
pronase. In addition, we tested five cases of anti-glomerular
basement membrane disease. One of these was negative after
pronase, as well as after proteinase XXIV digestion, one was
positive with both techniques, whereas the remaining three
were positive only after proteinase XXIV digestion. Finally, in
nine cases of membranous glomerulopathy, diagnostic IF-P
staining for IgG was obtained in six cases after pronase
digestion and in five cases after proteinase XXIV digestion.
In conclusion, we agree with Nasr et al. that IF-P is a
valuable salvage technique for renal biopsies. To this, we
would like to add that IF-P on sections digested with
proteinase XXIV is generally more sensitive than IF-P on
pronase-digested sections.
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To the Editor: I read with great interest the article on the
history of urinalysis in Western culture by Armstrong.1 It
gives a detailed outline of how uroscopy developed into a
prominent medical diagnostic tool, and later was abandoned
due to the poor scientific basis of such practice. In Dr
Amrstrong’s article, however, it is not mentioned that
uroscopy was so popular to be included in the most famous
play by Niccolo` Machiavelli, ‘La Mandragola (The Man-
drake)’,2,3 making fun of presumptuous physicians and
credulous patients. In another important paper on uroscopy
by Voswinckel,4 the contribution of Machiavelli is not
mentioned as well.
Niccolo` di Bernardo dei Machiavelli (May 3, 1469 to June
21, 1527) was an Italian political philosopher. He is a central
figure of the political component of the Italian Renaissance,
most widely known for his treatises on realist political theory
(The Prince). However, he also was a musician, poet, and
romantic comedic playwright.
The Mandragola has been widely performed and very
popular since the sixteenth century. The title comes from
the popular tale that a woman who drinks a potion made
from the mandrake root is certain to conceive a child, the
only drawback being that the man with whom she first has
sex after taking the potion will die within 8 days. The story
evolves around Callimaco, a lovesick Florentine who
came form Paris to conquer the heart (and the graces) of
Lucrezia, the beautiful young wife of Messer Nicia Calfucci, a
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